

ATTORNEY'S DOCKET NO: C01039.70075.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Krieg et al.
Serial No. : unassigned
Conf. No. : uassigned
Filed : Herewith
For : IMMUNOSTIMULATORY NUCLEIC ACIDS
Examiner : unknown
Art Unit : unknown

Mail Stop Patent Application

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited on the attached form PTO-1449 (modified) are enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Arthur M. Krieg, et al., Applicant

By: 
Alan W. Steele, Reg. No. 45,128
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. C01039.70075.US
Dated: July 3, 2003
Xx

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 6

FILING DATE: Herewith

APPLICANT: Krieg et al.

GROUP ART UNIT: unknown

EXAMINER: unknown

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	*	3,906,092		Hilleman et al.	09-16-1975
	*	5,023,243		Tullis	06-11-1991
	*	5,248,670		Draper et al.	09-28-1993
	*	5,585,479		Hoke et al.	12-17-1996
	*	5,663,153		Hutcherson et al.	09-02-1997
	*	5,723,335		Hutcherson et al.	03-03-1998
	*	5,786,189		Locht et al.	07-28-1998
	*	5,849,719		Carson et al.	12-15-1998
	*	6,194,388	B1	Krieg et al.	02-27-2001
	*	6,207,646	B1	Krieg et al.	03-27-2001
	*	6,214,806	B1	Krieg et al.	04-10-2001
	*	6,218,371	B1	Krieg et al.	04-17-2001
	*	6,239,116	B1	Krieg et al.	05-29-2001
	*	6,339,068	B1	Davis et al.	01-15-2002
		6,552,006	B2	Raz et al.	04-22-2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	*	EP	0468520	A3		01-29-1992	
	*	EP	0302758	B1		11-08-1989	
	*	WO	91/12811			09-05-1991	
	*	WO	92/03456			04-05-1992	
	*	WO	92/18522			10-29-1992	
	*	WO	92/21353			12-10-1992	
	*	WO	94/19945			09-15-1994	
	*	WO	95/05853			03-02-1995	
	*	WO	95/26204			10-05-1995	
	*	WO	96/02555	A1		02-01-1996	
	*	WO	96/35782			11-14-1996	
	*	WO	97/28259			08-07-1997	
	*	WO	98/14210			04-09-1998	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	ADYA N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. <i>Proc Natl Acad Sci USA</i> 91(12):5642-6, Jun. 7, 1994.	
	*	ANGIER N, Microbe DNA seen as alien by immune system, <i>New York Times</i> , Apr. 11, 1995.	
	*	AZAD RF et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region, <i>Antimicrobial Agents and Chemotherapy</i> , 37:1945-1954, Sep. 1993.	

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: unassigned	ATTY. DOCKET NO.: C01039.70075.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: Herewith	
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: unknown	EXAMINER: unknown
Sheet	2	of	6		

	*	AZUMA, Biochemical and immunological studies on cellular components of tubercle bacilli, <i>Kekkaku</i> , 69(9):45-55 (1992).		
	*	BALLAS ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol</i> 157(5):1840-5 (1996).		
	*	BAYEVER E, systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial, <i>Antisense Res Dev</i> , 3:383-390 (1993).		
	*	BENNETT RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. <i>J Clin Invest</i> 76(6):2182-90 (1985).		
	*	BIOLABS 1988-1989 Catalog, Random Primer #s 1230, 1601, 1602.		
	*	BLAXTER et al., Genes expressed in Brugia malayi infective third stage larvae, <i>Mol Biochem Parasitol</i> , 77:77-93 (Apr. 1996).		
	*	BOGGS RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev</i> 7(5):461-71, Oct. 1997.		
	*	BRANDA et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1, <i>Biochem Pharmacol</i> , 45(10):2037-2043 (1993).		
	*	BRANDA RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. <i>J Lab Clin Med</i> 128(3):329-38, Sep. 1996.		
	*	BRISKIN M et al., Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation, <i>Mol Cell Biol</i> , 10:1:422-5 (1990).		
	*	CHACE J et al., Regulation of differentiation in CD5+ and conventional B cells, <i>Clin Immunol Immunopathol</i> , 68(3):327-332 (1993).		
	*	CHANG YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. <i>J Virol</i> 64(1):264-77, Jan. 1990.		
	*	CHU RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>J Exp Med</i> 186(10):1623-31, Nov. 17, 1997.		
	*	COWDERY J et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides, <i>J Immunol</i> , 156:12:4570-5 (1996).		
	*	CROSBY SD et al., The early responses gene NGFI-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGGCG (GSG) element-binding protein family, <i>Mol Cell Biol</i> , 2:3835-3841 (1991).		
	*	CRYSTAL R, Transfer of genes to humans: early lessons and obstacles to success, <i>Science</i> , 270:404-410 (1995).		
	*	ENGLISCH et al., Chemically modified oligonucleotides as probes and inhibitors, <i>Angew Chem Int Ed Engl</i> , 30:613-629 (1991).		
	*	ERB KJ et al., Infection of mice with Mycobacterium bovis-bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. <i>J Exp Med</i> 187(4):561-9, Feb. 16, 1998.		
	*	ETLINJER, Carrier sequence selection--one key to successful vaccines, <i>Immunology Today</i> , 13(2):52-55 (1992).		
	*	European Patent Office, International Search Authority--Search Report, PCTUS95/01570, Jul. 11, 1995.		
	*	FOX RI, Mechanism of action of hydroxychloroquine as an antirheumatic drug, <i>Chem Abstracts</i> 120:15, Abstract No. 182630 (Apr. 29, 1994).		
	*	GURA T, Antisense has growing pains, <i>Science</i> , 270:575-576 (1995).		
	*	HADDEN J et al., Immunopharmacology, <i>JAMA</i> , 268:20:2964-2969 (1992).		
	*	HADDEN J et al., Immunostimulants, <i>TIPS</i> , 141:169-174 (1993).		
	*	HALPERN MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol</i> 167(1):72-8 (1996).		

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: unassigned	ATTY. DOCKET NO.: C01039.70075.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: Herewith	
				APPLICANT: Krieg et al.	
Sheet	3	of	6	GROUP ART UNIT: unknown	EXAMINER: unknown

*	HATZFELD J, Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor β 1 or Rb oligonucleotides, <i>J Exp Med</i> , 174:925-929 (1991).		
*	HIGHFIELD PE, Sepsis: the more, the murkier, <i>Biotechnology</i> , 12:828, Aug. 12, 1994.		
*	HOEFFLER JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. <i>Mol Endocrinol</i> 5(2):256-66, Feb. 1991.		
*	IGUCHI-ARIGA SM et al., CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. <i>Genes Dev</i> 3(5):612-9, May 1989.		
*	ISHIKAWA R et al., IFN induction and associated changes in splenic leukocyte distribution. <i>J Immunol</i> 150(9):3713-27, May 1, 1993.		
*	IVERSEN P et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion, <i>Antisense Res Dev</i> , 4:43-52 (1994).		
*	JAKWAY J et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products, <i>J Immunol</i> , 137:7:2225-31 (1996).		
*	JAROSZEWSKI J et al., Cellular uptake of antisense oligonucleotides, <i>Adv Drug Delivery Rev</i> , 6:3:235-50 (1991).		
*	KATAOKA T et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG, <i>Jpn J Cancer Re.</i> , 83:244-247, Mar. 1992.		
*	KIMURA Y et al., Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN, <i>J Biochem</i> , 116(5):991-994 (1994).		
*	KLINE JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. <i>J Invest Med</i> 44(7):380A (1996).		
*	KLINE JN et al., CpG oligonucleotides can reverse as well as prevent TH2-mediated inflammation in a murine model of asthma. <i>J Invest Med</i> 45(7):298A (1997).		
*	KLINE JN et al., Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma. <i>J Invest Med</i> 45(3):282A (1997).		
*	KLINMAN DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci USA</i> 93(7):2879-83 (1996).		
*	KRIEG AM et al, Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?, <i>Antisense Res Dev</i> , 5:241 (1995).		
*	KRIEG AM et al, The role of CpG dinucleotides in DNA vaccines, <i>Trends in Microbiology</i> , 6:23-27, Jan. 1998.		
*	KRIEG AM et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation, <i>J Immunol</i> 143(8):2448-51, Oct. 15, 1989.		
*	KRIEG AM et al., CpG DNA: A pathogenic factor in systemic lupus erythematosus? <i>J Clin Immunol</i> , 15(6):284-292 (1995).		
*	KRIEG AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> 374:546-9, 6 Apr. 1995.		
*	KRIEG AM et al., Leukocyte stimulation by oligodeoxynucleotides, <i>Applied Antisense Oligonucleotide Technology</i> 431-448 (1998),.		
*	KRIEG AM et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholestryloxy moiety increases cellular association and improves efficacy, <i>Proc Natl Acad Sci USA</i> , 90:1048-1052 (1993).		
*	KRIEG AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev</i> 6(2):133-9, Summer 1996.		

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 4 of 6

FILING DATE: Herewith

APPLICANT: Krieg et al.

GROUP ART UNIT: unknown

EXAMINER: unknown

	*	KRIEG AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <i>Antisense Res Dev</i> 1(2):161-71, Summer 1991.		
	*	KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation, <i>Jpn J Cancer Res</i> , 83:1128-1131, Nov. 1992.		
	*	LEONARD GA et al., Conformation of guanine 8-oxoadenine base pairs in the crystal structure of d(CGCGAATT(O8A)GCG), <i>Biochemistry</i> , 31(36):8415-8420 (1992).		
	*	LIPFORD G et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants, <i>Eur J Immunol</i> , 27(9):2340-4 (1997).		
	*	LIPFORD G et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines, <i>Eur J Immunol</i> , 12(27):3420-3426 (1997).		
	*	MACFARLANE DE et al., Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. <i>J Immunol</i> 160(3):1122-31, Feb. 1, 1998.		
	*	MASTRANGELO MJ et al., Gene therapy for human cancer: an essay for clinicians. <i>Seminars Oncology</i> , 23(1):4-21 (1996).		
	*	MATSON S et al., Nonspecific suppression of [³ H]thymidine incorporation by control oligonucleotides. <i>Antisense Res Dev</i> 2(4):325-30, Winter 1992.		
	*	MCINTYRE K et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation, <i>Antisense Res Dev</i> , 3(4):309-322 (1993).		
	*	MESSINA et al., Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA, <i>J Immunol</i> , 147(6):1759-1764, Sep. 15, 1991.		
	*	MESSINA, et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens, <i>Cell Immunol</i> , 147:148-157 (1993).		
	*	MOJCIK C et al., Administration of a phosphorothioate oligonucleotide antisense murine endogenous retroviral MCF env causes immune effect in vivo in a sequence-specific manner, <i>Clin Immunol Immunopathol</i> , 67(2):130-136 (1993).		
	*	MOTTRAM et al., A novel CDC2-related protein kinase from leishmania mexicana, LmmCRK1, is post-translationally regulated during the life cycle, <i>J Biol Chem</i> , 268:28 21044-21052 (Oct. 1993).		
	*	NYCE J et al., DNA antisense therapy for asthma in an animal model, <i>Nature</i> , 385:721-5 (1997).		
	*	PISETSKY D, Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides, <i>Molecular Biology Reports</i> , 18:217-221 (1993).		
	*	PISETSKY DS et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. <i>Life Science</i> , 54:101-107 (1994).		
	*	PISETSKY DS, Immunological consequences of nucleic acid therapy, <i>Antisense Res Dev</i> , 5:219-225 (1995).		
	*	PISETSKY DS, The immunological properties of DNA, <i>J Immunol</i> , 156:421-423 (1996).		
	*	QUDDUS J et al., Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. <i>J Clin Invest</i> 92(1):38-53, Jul. 1993.		
	*	RAZ E et al., Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses, <i>Proc Natl Acad Sci USA</i> , 91:9519-9523 (1994).		
	*	ROJANASAKUL Y, Antisense oligonucleotide therapeutics: drug delivery and targeting, <i>Advanced Drug Delivery Reviews</i> , 18:115-131 (1996).		
	*	ROMAN M et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. <i>Nat Med</i> 3(8):849-854, Aug. 1997.		
	*	SATO et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization, <i>Science</i> , 273:352-354 (1996).		

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 5 of 6

FILING DATE: Herewith

APPLICANT: Krieg et al.

GROUP ART UNIT: unknown

EXAMINER: unknown

	*	SCHNELL N et al., Identification and characterization of a <i>Saccharomyces cerevisiae</i> gene (PAR1) conferring resistance to iron chelators, <i>Eur J Biochem</i> , 200:487-493 (1991).		
	*	SCHWARTZ DA et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. <i>J Clin Invest</i> 100(1):68-73, Jul. 1, 1997.		
	*	SHIRAKAWA T et al., The inverse association between tuberculin responses and atopic disorder. <i>Science</i> 275(5296):77-9, Jan. 3, 1997.		
	*	SPARWASSER T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol</i> 27(7):1671-9, Jul. 1997.		
	*	STEIN CA et al., Oligodeoxynucleotides as inhibitors of gene expression: a review, <i>Cancer Res</i> , 48:2659-2668 (1988).		
	*	STULL RA et al., Antigene, ribozyme, and aptamer nucleic acid drugs: progress and prospects, <i>Pharm Res.</i> , 12(4):465-483 (1995).		
	*	SUBRAMANIAN et al., Theoretical considerations on the 'spine of hydration' in the minor groove of d(CGCGAATTGCG) d(CGGCTTAAGCGC): Monte Carlo computer simulation, <i>Proc Natl Acad Sci USA</i> , 85:1836-1840, Mar. 1988.		
	*	TANAKA T et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts stimulates B cell DNA synthesis and inhibits immunoglobulin secretion, <i>J Exp Med</i> , 175: 597-607 (1992).		
	*	The New England Biolabs Catalog, 1988-1989, item #1230.		
	*	TOKUNAGA T et al., A synthetic single-stranded DNA, poly (dG, dC), induces interferon- α/β and - γ , augments natural killer activity and suppresses tumor growth, <i>Jpn J Cancer Res</i> , 79:682-686, Jun. 1988.		
	*	TOKUNAGA T et al., synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells, <i>Microbiol Immunol</i> , 36(1):55-66 (1992).		
	*	UHLMANN, et al., Antisense oligonucleotides: a new therapeutic principle, <i>Chem Rev</i> , 90:543-584 (1990).		
	*	WAGNER RW, Gene inhibition using antisense oligodeoxynucleotides, <i>Nature</i> , 372:333-335 (1994).		
	*	WALLACE et al., Oligonucleotide probes for the screening of recombinant DNA libraries, <i>Methods Enzymol</i> , 152:432-442 (1987).		
	*	WEISS R, Upping the antisense ante: scientists bet on profits from reverse genetics, <i>Science</i> , 139:108-109 (1991).		
	*	WHALEN RG, DNA vaccines for emerging infection diseases: what if?, <i>Emerg Infect Dis</i> , 2(3):168-175 (1996).		
	*	WU GY et al., Receptor-mediated gene delivery and expression in vivo, <i>J Biol Chem</i> , 263:14621-14624 (1988).		
	*	WU-PONG S, Oligonucleotides: opportunities for drug therapy and research, <i>Pharmaceutical Technology</i> , 18:102-114 (1994).		
	*	YAMAMOTO S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells, and inhibits tumor growth, <i>Microbiol Immunol</i> , 36(9):983-997 (1992).		
	*	YAMAMOTO S et al., In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res</i> 79:866-73, Jul. 1988.		
	*	YAMAMOTO S et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce and augment INF-mediated natural killer activity, <i>J Immunol</i> , 148(12):4072-4076, Jun. 15, 1992.		
	*	YAMAMOTO S, Mode of action of oligonucleotide fraction extracted from <i>Mycobacterium bovis</i> BCG, <i>Kekkaku</i> , 69(9):29-32 (1994).		

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: unassigned	ATTY. DOCKET NO.: C01039.70075.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: Herewith	
				APPLICANT: Krieg et al.	
Sheet	6	of	6	GROUP ART UNIT: unknown	EXAMINER: unknown

	*	YAMAMOTO T et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length, <i>Antisense Res Dev</i> , 4:119-123 (1994).		
	*	YAMAMOTO T et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence AACGTT to murine splenocytes enhances interferon production and natural killer activity, <i>Microbiol Immunol</i> , 38(10):831-836 (1994).		
	*	YAMAMOTO T et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro, <i>Jpn J Cancer Res</i> , 85:775-779 (1994).		
	*	YI AK et al., IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligonucleotides, <i>J Immunol</i> , 156:558-564 (1996).		
	*	YI AK et al., Rapid immune activation by CpG motifs in bacterial DNA, <i>J Immunol</i> , 157:5394-5402 (1996).		
	*	ZHAO Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <i>Antisense Res Dev</i> 3(1):53-66, Spring 1993.		
	*	ZHAO Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. <i>Blood</i> 84(11):3660-6, Dec. 1, 1994.		

EXAMINER	DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed on March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]